Evicenter
MarkdownMedical informationP&T meetings
Vonaprument (ANX007)

Geographic atrophy secondary to age-related macular degeneration

Launch
Not announced
Last updated
167 sources

Section 4 of 6

Clinical evidence

214 evidence topics · 51 sources

Study summaries

ARCHER II

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using confirmed best-corrected visual acuity loss of 15 or more ETDRS letters as the primary endpoint
Functional primary endpoints of approved retinal products
Statistical analysis description
Number of participants (Planned and analyzed)
Number analyzed

No evidence found.

Description of analysis sets
Definitions of efficacy and safety analysis populations

No evidence found.

Results
Participant disposition
Disposition by treatment arm

No evidence found.

Baseline characteristics
Demographic and structural characteristics compared with ARCHER
CharacteristicARCHER (N = 270)ARCHER II (N = 659)
Age, mean (SD)“80.0 (8.2)”“78.4 (8.0)”
Female“61.5%”“63.0%”
GA lesion size (mm2), mean (SD)“7.36 (4.01)”“7.23 (3.49)”
GA lesion location, subfoveal“51.9%”“54.8%”
Total EZ loss, mm2 (% of total area lost)“12.7 (35.3%)”“12.3 (34.3%)”
Visual acuity characteristics compared with ARCHER
CharacteristicARCHER (N = 270)ARCHER II (N = 659)
Mean BCVA (SD), letters“58.4 (16.2)”“65.8 (10.5)”
Baseline BCVA below 45 letters“23.3%”“0.0%”
Mean LLVA (SD), letters“33.0 (16.9)”“38.3 (17.2)”
Mean LLVD (SD), letters“25.7 (16.9)”“27.6 (15.6)”
LLVD below 30 letters“62.4%”“60.7%”
Baseline characteristics by treatment arm

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary: design features and absence of results

As of November 15, 2026, no efficacy or safety result of ARCHER II has been released; the sponsor expects the independent Data Monitoring Committee assessment of the Month 15 primary endpoint in the fourth quarter of 2026, sub-study results in the first quarter of 2027 if the endpoint is met, and study completion with the Month 24 analyses in the third quarter of 2027. The only disclosed trial-level data are pooled, masked baseline characteristics of 659 participants and sponsor statements on retention (90%), discontinuation (below 10%), and compliance (above 95%); baseline data by arm and the numbers analyzed have not been published.

The design has changed since it was first announced. In December 2023 the trial was planned with approximately 400 participants randomized 1:1 and a primary endpoint assessed through 12 months; the enrolled trial randomized 659 participants 2:1 to monthly vonaprument 5 mg or sham. The timing of the primary analysis was described as 12 to 18 months from dosing initiation in 2024, at least 12 months in July 2025, 12 to 15 months in December 2025, and Month 15 in 2026. A Month 24 dual primary endpoint was added in August 2026 while masked follow-up was ongoing, with alpha allocated between the two timepoints (the majority to Month 15); the sponsor's Form 10-Q states that there is no assurance regulators will accept the amended dual primary endpoint design.

For the U.S. filing, the single protocol is divided into two pre-defined sub-studies of about 330 participants each to address the FDA two-trial recommendation, so the replication rests on two subsets of one trial with a shared protocol and conduct. The sham comparator is an injection-free procedure, and the planned injection-controlled trial against pegcetacoplan (ARROW) was dropped in March 2025, so ARCHER II will provide no comparison with an approved GA therapy. The endpoint rationale rests on the phase 2 ARCHER trial, in which the 15-letter loss analysis was prespecified while the primary lesion-growth endpoint “did not reach statistical significance”. Eligibility excludes eyes with baseline BCVA below 45 letters, which the sponsor states was chosen because few such eyes had 15-letter loss events in ARCHER; results will therefore not describe eyes with lower baseline acuity. Patient-reported outcomes are listed as a secondary objective in the EU record, and no instrument has been named.

ARCHER

Objective
Location and study date
Registered study dates
MilestoneRegistry record
Study start (actual)“2021-02-26”
Primary completion (actual)“2023-03-28”
Study completion (actual)“2023-09-13”
Study site countries
Study design
Registered design elements
Design elementRegistry record
Phase“Phase 2”
Allocation“Randomized”
Intervention model“Parallel Assignment”
Masking“Quadruple”
Primary purpose“Treatment”
Eligibility criteria
Treatment
Registered arms and interventions
Study outcomes
Rationale for using rate of change in geographic atrophy lesion area by fundus autofluorescence as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed by population and arm
PopulationANX007 EMANX007 EOMSham
Baseline (ITT)“89”“92”“89”
Primary endpoint (non-subfoveal at baseline)“38”“43”“45”
LLVA and LLVD ≥15-letter loss events“79”“85”“79”
Safety“89”“92”“89”
PopulationANX007 pooled
Primary endpoint (non-subfoveal at baseline)“81”
Description of analysis sets
Results
Participant disposition
Registry participant flow through the overall study
Milestone or reasonANX007 EMANX007 EOMSham
Started“89”“92”“89”
Received at least 1 dose of study drug“89”“92”“89”
Completed“73”“77”“76”
Not completed“16”“15”“13”
Adverse event“4”“7”“3”
Death“0”“0”“1”
Lost to follow-up“2”“2”“1”
Other than specified“1”“0”“1”
Physician decision“1”“0”“1”
Protocol violation“1”“1”“0”
Withdrawal by subject“7”“5”“6”
Treatment discontinuation by arm
MeasureSham pooledANX007 EMANX007 EOM
Discontinued treatment“10 (11.2%)”“13 (14.6%)”“11 (12.0%)”
Baseline characteristics
Registry baseline characteristics, ITT population
CharacteristicANX007 EMANX007 EOMShamTotal
Participants“89”“92”“89”“270”
Age, years, mean (SD)“79.7(8.64)”“80.5(8.53)”“79.8(7.49)”“80.0(8.22)”
Female, participants“47”“60”“59”“166”
Male, participants“42”“32”“30”“104”
Hispanic or Latino, participants“1”“2”“3”“6”
White, participants“87”“89”“87”“263”
Asian, participants“1”“2”“2”“5”
Study eye GA lesion size, mm², mean (SD)“7.2789(3.96342)”“7.5284(4.09946)”“7.2802(3.98783)”“7.3643(4.00505)”
BCVA, ETDRS letters, mean (SD)“58.8(17.19)”“57.9(15.30)”“58.5(16.23)”“58.4(16.19)”
LLVA, ETDRS letters, mean (SD)“35.3(16.41)”“29.6(15.72)”“34.2(18.05)”“33.0(16.86)”
LLVA and LLVD, participants analyzed“87 participants”“91 participants”“85 participants”“263 participants”
LLVD, ETDRS letters, mean (SD)“23.5(16.08)”“28.3(18.39)”“25.0(15.70)”“25.7(16.86)”
Lesion location, lesion size category, fellow-eye CNV, and multifocality
CharacteristicSham pooled (N=89)Vonaprument EM (N=89)Vonaprument EOM (N=92)
Foveal lesion“49.4%”“57.3%”“53.3%”
GA lesion < 7.5 mm²“61.8%”“58.4%”“57.6%”
Fellow eye CNV“22.5%”“24.7%”“17.4%”
Multifocality, n (%)“65 (73.0%)”“61 (68.5%)”“67 (72.8%)”
Efficacy results
Confirmed BCVA ≥15-letter loss: registry event counts, secondary outcome
MeasureANX007 EMANX007 EOMSham
Participants analyzed“89”“92”“89”
Number of events with confirmed ≥15-letter loss“4”“8”“15”
Confirmed BCVA ≥15-letter loss: final data under two event definitions
Event definition and measureShamVonaprument EMVonaprument EOM
Through month 12 or last visit: participants with loss“19/89”“5/89”“9/92”
Through month 12 or last visit: percentage“21.3%”“5.6%”“9.8%”
Through month 12 or last visit: nominal p-value vs pooled sham“---”“0.0021”“0.032”
Month 12 event confirmed at month 15: participants with loss“15/89”“4/89”“8/92”
Month 12 event confirmed at month 15: percentage“16.9%”“4.5%”“8.7%”
Month 12 event confirmed at month 15: nominal p-value vs pooled sham“---”“0.0076”“0.0994”
Confirmed BCVA ≥10-letter and ≥20-letter loss: sensitivity analysis
Threshold and measureShamEMEOM
≥10-letter loss: participants with loss“23/89”“14/89”“19/92”
≥10-letter loss: percentage“25.8%”“15.7%”“20.7%”
≥10-letter loss: nominal p-value vs sham“---”“0.096”“0.408”
≥20-letter loss: participants with loss“15/89”“4/89”“6/92”
≥20-letter loss: percentage“16.9%”“4.5%”“6.5%”
≥20-letter loss: nominal p-value vs sham“---”“0.008”“0.030”
Low-luminance visual acuity: registry results
MeasureANX007 EMANX007 EOMSham
Change from baseline to month 12, least squares mean (SE), letters“-1.4(1.29)”“-2.8(1.25)”“-4.8(1.31)”
Participants analyzed for ≥15-letter loss“79”“85”“79”
Number of events with ≥15-letter LLVA loss“6”“8”“16”
Low-luminance visual acuity and deficit: final data
MeasureShamEMEOM
LLVA ≥15-letter loss: participants with loss“16/79”“6/79”“8/85”
LLVA ≥15-letter loss: percentage“20.3%”“7.6%”“9.4%”
LLVA ≥15-letter loss: nominal p-value vs sham“--”“0.0216”“0.0497”
LLVD ≥15-letter worsening: participants with worsening“13/79”“4/79”“8/85”
LLVD ≥15-letter worsening: percentage“16.5%”“5.1%”“9.4%”
LLVD ≥15-letter worsening: nominal p-value vs sham“--”“0.0209”“0.1774”
Mean change in LLVA at month 12“-4.8”“-1.4”“-2.8”
Mean change in LLVA at month 12: nominal p-value vs sham“---”“0.0592”“0.2664”
Low-luminance visual deficit: registry results
MeasureANX007 EMANX007 EOMSham
Change from baseline to month 12, least squares mean (SE), letters“-0.4(1.55)”“1.3(1.50)”“0.6(1.57)”
Participants analyzed for ≥15-letter worsening“79”“85”“79”
Number of events with ≥15-letter LLVD worsening“4”“8”“13”
Subgroup analysis: low-luminance visual deficit worsening by baseline BCVA
Post hoc analysis: participants with subfoveal lesions at baseline
Measure, subfoveal populationShamVonaprument EMVonaprument EOM
Confirmed BCVA ≥15-letter loss: participants with loss“10/44”“3/51”“7/49”
Confirmed BCVA ≥15-letter loss: percentage“22.7%”“5.9%”“14.3%”
Confirmed BCVA ≥15-letter loss: nominal p-value vs sham“---”“.0172”“.2930”
LLVA ≥15-letter loss: participants with loss“7/41”“2/50”“1/48”
LLVA ≥15-letter loss: percentage“17.1%”“4.0%”“2.1%”
LLVA ≥15-letter loss: nominal p-value vs sham“---”“.0137”“.0377”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Deaths, serious adverse events, and other adverse events, registry results
MeasureANX007 EMANX007 EOMSham
All-cause mortality“2/89 (2.25%)”“3/92 (3.26%)”“2/89 (2.25%)”
Participants with serious adverse events“21/89 (23.60%)”“16/92 (17.39%)”“16/89 (17.98%)”
Participants with other (non-serious) adverse events“21/89 (23.60%)”“20/92 (21.74%)”“23/89 (25.84%)”
Ocular serious adverse events, registry results
Non-ocular serious adverse events in two or more participants in any group, registry results
Non-serious adverse events at a frequency of 5% or more, registry results
Adverse events of special interest: choroidal neovascularization, endophthalmitis, vascular occlusion, vasculitis, intraocular inflammation, and ischemic optic neuropathy
Adverse event, n (%)Sham (N=89)Vonaprument EM (N=89)Vonaprument EOM (N=92)
Choroidal neovascularization“3 (3.4%)”“4 (4.5%)”“4 (4.3%)”
Endophthalmitis“0”“1 (1.1%)”“2 (2.2%)”
Retinal vascular occlusion“0”“0”“1^ (1.1%)”
Retinal vasculitis“0”“0”“0”
Intraocular inflammation“0”“2 (2.2%)”“1 (1.1%)”
Ischemic optic neuropathy“0”“0”“0”
Study limitations
Summary: missed primary endpoint, reliance on secondary and post hoc analyses, and unpublished results
  • Primary endpoint: ARCHER did not meet its primary endpoint, the rate of change (slope) in geographic atrophy lesion area by fundus autofluorescence from baseline to month 12. In the registry analysis, which included non-subfoveal participants only, the slope was 2.0837 mm²/year in 81 participants receiving pooled vonaprument and 1.9019 mm²/year in 45 participants receiving sham. Annexon reported reductions in lesion growth of 6.2% with monthly dosing (p=0.526), 1.3% with every-other-month dosing (p=0.896), and 3.7% for the pooled groups (p=0.673).
  • Efficacy claims rest on secondary, exploratory, and post hoc analyses: BCVA ≥15-letter loss is a secondary outcome on the registry record and is labeled “A Prespecified Secondary Analysis” in a 2025 presentation. The Form 10-K describes the monthly-arm result as “nominally statistically significant”, and the company presentations of 2024 to 2026 label their p-values as nominal. The analyses of eyes with subfoveal lesions are labeled post hoc, and the company describes the analyses of less advanced disease, BCVA ≥10-letter and ≥20-letter loss, fellow eyes, and the off-treatment period as additional or sensitivity analyses. Mean change in BCVA at month 12 was -1.7 letters with monthly dosing, -2.6 with every-other-month dosing, and -4.1 with sham, with nominal p-values of 0.1904 and 0.3977.
  • Discrepant event counts: the registry reports 4, 8, and 15 events of confirmed BCVA ≥15-letter loss (monthly, every other month, sham), defined as loss at 2 consecutive visits. The topline release reported 5 of 89 (5.6%), 10 of 92 (10.9%), and 19 of 89 (21.3%) participants, counting loss on two consecutive visits or a loss at the end of the 12-month treatment period. The 2026 presentation reports 5 of 89, 9 of 92, and 19 of 89 under “two consecutive visits through month 12 or at last study visit” (nominal p=0.0021 and 0.032), and 4 of 89, 8 of 92, and 15 of 89 when the month 12 event is confirmed at month 15 (nominal p=0.0076 and 0.0994). Under the definition that reproduces the registry counts, the every-other-month result is not nominally significant.
  • Changing analyses between presentations: the topline release reported LLVA ≥15-letter loss in 8 of 79 participants (10.1%) with monthly dosing and 16 of 79 (20.3%) with sham (p=0.076), described as a “non-significant trend”. Later presentations report 6 of 79 (7.6%) with p=0.022 or 0.0216; the 2024 presentation attributes these counts to a “single LLVA ≥15-letter loss event”, and the 2026 presentation attributes the same counts to “two consecutive or last visit 15-letter loss events”. The nominal p-value for the monthly hazard ratio of 0.272 is 0.0098 in the 2024 presentation and 0.0119 in the 2026 presentation, and for the every-other-month hazard ratio of 0.504 it is 0.0788 and 0.1098. The ellipsoid zone result across the full retinal field was 29% (p=0.017) in the 2024 release and a 27% decrease (p=0.0457) in 107 vonaprument and 67 sham participants in the 2026 presentation; the central 1.5 mm and 2.0 mm subdomain analyses include 46 and 61 participants.
  • No peer-reviewed publication: no journal article reporting ARCHER results was identified. The registry record states a restrictive agreement under which investigator-initiated publications wait until all protocol-defined results are published in a manuscript. The available results come from the registry, press releases, the Form 10-K, investor presentations, and congress presentations that state Annexon sponsorship, with authors who are employees and equity owners of Annexon Biosciences.
  • Applicability: the treatment period was 12 months, followed by 6 months off treatment, during which the rate of BCVA ≥15-letter loss in the treated groups increased to parallel sham. Ninety-six percent of participants were enrolled in the United States. ARCHER II did not enroll individuals with baseline BCVA <45 letters, because ARCHER showed a very low incidence of BCVA 15-letter loss in that group, so the phase 3 population differs from the phase 2 population. The phase 3 trial tests monthly dosing only.

AiiM OLE

Objective
Location and study date
Registry dates for the extension study
MilestoneRegistry record
First posted“2026-09-08”
Study start (estimated)“2026-09-30”
Primary completion (estimated)“2029-07-31”
Study completion (estimated)“2029-07-31”
Extension study identifiers
ItemRegistry record
Sponsor protocol number“ANX007-GA-03”
EU CT number“2026-527023-96-00”
Acronym“AiiM OLE”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Estimated enrollment in the extension study
ItemRegistry record
Estimated enrollment“605”
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary: extension study not yet started

The AiiM OLE study (NCT07807969) was registered as not yet recruiting, with an estimated start date of September 30, 2026 and an estimated primary completion date of July 31, 2029, so no participant data exist. It is a single-group, open-label design with no masking and no comparator arm, and its registered primary outcome is the number of participants with treatment-emergent adverse events through Month 24; any efficacy observations it yields will lack a concurrent control. Enrollment is limited to participants who completed ARCHER II and had not permanently ceased their assigned masked treatment at or before the Month 24 visit, so the extension population is a selected subset of the ARCHER II population. The company states that the extension is designed to evaluate the “longer-term profile of vonaprument for inclusion in the label”, and its 10-Q states that there is no assurance that regulators will accept data from the OLE study.

ANX007-GLA-02

Objective
Location and study date
Registry dates for the phase 1b study
MilestoneRegistry record
Study start (actual)“2018-07-25”
Primary completion (actual)“2019-06-03”
Study completion (actual)“2019-06-03”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics of the phase 1b study by arm
CharacteristicSham (n = 6)ANX007 2.5 mg (n = 6)ANX007 5.0 mg (n = 5)Overall (n = 17)
Age, mean (SD), yr“70.2 (22.8)”View highlighted excerpt for this quote“60.3 (16.2)”View highlighted excerpt for this quote“74.0 (8.0)”View highlighted excerpt for this quote“67.8 (17.2)”View highlighted excerpt for this quote
Age, median (min, max), yr“79.5 (24, 82)”View highlighted excerpt for this quote“58.5 (35, 78)”View highlighted excerpt for this quote“74.0 (65, 86)”View highlighted excerpt for this quote“75.0 (24, 86)”View highlighted excerpt for this quote
Male, n (%)“4 (66.7)”View highlighted excerpt for this quote“2 (33.3)”View highlighted excerpt for this quote“2 (40.0)”View highlighted excerpt for this quote“8 (47.1)”View highlighted excerpt for this quote
Female, n (%)“2 (33.3)”View highlighted excerpt for this quote“4 (66.7)”View highlighted excerpt for this quote“3 (60.0)”View highlighted excerpt for this quote“9 (52.9)”View highlighted excerpt for this quote
Black/African American, n (%)“0”View highlighted excerpt for this quote“1 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (5.9)”View highlighted excerpt for this quote
Asian, n (%)“1 (16.7)”View highlighted excerpt for this quote“1 (16.7)”View highlighted excerpt for this quote“1 (20.0)”View highlighted excerpt for this quote“3 (17.6)”View highlighted excerpt for this quote
White, n (%)“5 (83.3)”View highlighted excerpt for this quote“4 (66.7)”View highlighted excerpt for this quote“4 (80.0)”View highlighted excerpt for this quote“13 (76.5)”View highlighted excerpt for this quote
Weight, mean (SD), kg“74.8 (20.3)”View highlighted excerpt for this quote“79.7 (10.1)”View highlighted excerpt for this quote“88.4 (15.0)”View highlighted excerpt for this quote“80.5 (15.8)”View highlighted excerpt for this quote
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events in the phase 1b study by arm
n (%)Sham (n = 6)ANX007 2.5 mg (n = 7)ANX007 5 mg (n = 5)Overall (n = 18)
Any TEAE“2 (33.3)”View highlighted excerpt for this quote“2 (33.3)”View highlighted excerpt for this quote“2 (40.0)”View highlighted excerpt for this quote“6 (33.3)”View highlighted excerpt for this quote
Ocular disorders“2 (33.3)”View highlighted excerpt for this quote“2 (33.3)”View highlighted excerpt for this quote“2 (40.0)”View highlighted excerpt for this quote“6 (33.3)”View highlighted excerpt for this quote
Infection“0”View highlighted excerpt for this quote“1 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (5.5)”View highlighted excerpt for this quote
Injury“0”View highlighted excerpt for this quote“1 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (5.5)”View highlighted excerpt for this quote
Treatment-related TEAE“2 (33.3)”View highlighted excerpt for this quote“1 (16.7)”View highlighted excerpt for this quote“2 (40.0)”View highlighted excerpt for this quote“5 (27.8)”View highlighted excerpt for this quote
Conjunctival hemorrhage“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (20.0)”View highlighted excerpt for this quote“1 (5.5)”View highlighted excerpt for this quote
Conjunctival hyperemia“0”View highlighted excerpt for this quote“1 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (5.5)”View highlighted excerpt for this quote
Eye irritation“1 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (20.0)”View highlighted excerpt for this quote“2 (11.1)”View highlighted excerpt for this quote
Foreign body sensation in eyes“1 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (5.5)”View highlighted excerpt for this quote
Ocular hyperemia“1 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (5.5)”View highlighted excerpt for this quote
Vision blurred“1 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (5.5)”View highlighted excerpt for this quote
Study limitations
Summary: glaucoma population, small sample, and short follow-up

ANX007-GLA-02 enrolled participants with primary open-angle glaucoma, a population that differs from the geographic atrophy population of the phase 2 and phase 3 trials. Seventeen participants received study treatment (sham, 6; 2.5 mg, 6; 5 mg, 5), follow-up lasted 12 weeks with 2 injections given 4 weeks apart, and no formal comparisons or hypothesis testing were planned, so the results are descriptive. The safety table lists 7 participants in the 2.5-mg column and 18 overall, while the text reports 6 participants treated with 2.5 mg and 17 treated overall. Target engagement was measured in aqueous humor, which the authors state is “anticipated to represent” inhibition of C1q in the retina, supported by nonhuman primate data on file. The 5-mg dose was given in 100 μL in this study, while the ongoing phase 3 ARCHER II trial administers 5 mg in a 25-microliter dose. Low-level anti-drug antibody positivity was detected in 7 participants, including 1 in the sham group, which the authors attribute to likely false positives in the assay.

ANX007-GLA-01

Objective
Location and study date
Registry dates for the phase 1a study
MilestoneRegistry record
Study start (actual)“2018-03-23”
Primary completion (actual)“2018-08-03”
Study completion (actual)“2018-08-03”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics of the phase 1a study by dose cohort
CharacteristicANX007 1.0 mg (n = 3)ANX007 2.5 mg (n = 3)ANX007 5.0 mg (n = 3)Overall (n = 9)
Age, mean (SD), yr“66.3 (12.5)”View highlighted excerpt for this quote“70.7 (4.0)”View highlighted excerpt for this quote“72.7 (3.5)”View highlighted excerpt for this quote“69.9 (7.4)”View highlighted excerpt for this quote
Age, median (min, max), yr“66.0 (54, 79)”View highlighted excerpt for this quote“73.0 (66, 73)”View highlighted excerpt for this quote“73.0 (69, 76)”View highlighted excerpt for this quote“73.0 (54, 79)”View highlighted excerpt for this quote
Male, n (%)“1 (33.3)”View highlighted excerpt for this quote“3 (100.0)”View highlighted excerpt for this quote“2 (66.7)”View highlighted excerpt for this quote“6 (66.7)”View highlighted excerpt for this quote
Female, n (%)“2 (66.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (33.3)”View highlighted excerpt for this quote“3 (33.3)”View highlighted excerpt for this quote
Black/African American, n (%)“1 (33.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote
Asian, n (%)“0”View highlighted excerpt for this quote“2 (66.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (22.2)”View highlighted excerpt for this quote
White, n (%)“2 (66.7)”View highlighted excerpt for this quote“1 (33.3)”View highlighted excerpt for this quote“3 (100.0)”View highlighted excerpt for this quote“6 (66.7)”View highlighted excerpt for this quote
Weight, mean (SD), kg“105.2 (6.7)”View highlighted excerpt for this quote“83.7 (7.2)”View highlighted excerpt for this quote“82.2 (15.6)”View highlighted excerpt for this quote“90.3 (14.5)”View highlighted excerpt for this quote
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events in the phase 1a study by dose cohort
n (%)ANX007 1 mg (n = 3)ANX007 2.5 mg (n = 3)ANX007 5 mg (n = 3)Overall (n = 9)
Any TEAE“3 (100.0)”View highlighted excerpt for this quote“3 (100.0)”View highlighted excerpt for this quote“3 (100.0)”View highlighted excerpt for this quote“9 (100.0)”View highlighted excerpt for this quote
Ocular disorders“3 (100.0)”View highlighted excerpt for this quote“3 (100.0)”View highlighted excerpt for this quote“2 (66.7)”View highlighted excerpt for this quote“8 (88.9)”View highlighted excerpt for this quote
Infection“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (33.3)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote
Treatment-related TEAE“3 (100.0)”View highlighted excerpt for this quote“3 (100.0)”View highlighted excerpt for this quote“2 (66.7)”View highlighted excerpt for this quote“8 (88.9)”View highlighted excerpt for this quote
Conjunctival hemorrhage“0”View highlighted excerpt for this quote“2 (66.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (22.2)”View highlighted excerpt for this quote
Conjunctival hyperemia“3 (100.0)”View highlighted excerpt for this quote“3 (100.0)”View highlighted excerpt for this quote“2 (66.7)”View highlighted excerpt for this quote“8 (88.9)”View highlighted excerpt for this quote
Eye irritation“2 (66.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (22.2)”View highlighted excerpt for this quote
Study limitations
Summary: glaucoma population, small open-label cohorts, and serum-only pharmacodynamics

ANX007-GLA-01 was a first-in-human, open-label, single-dose escalation study in 9 participants with primary open-angle glaucoma (3 per dose cohort of 1.0, 2.5, and 5.0 mg), a population that differs from the geographic atrophy population of the phase 2 and phase 3 trials. The study had no masking and no control arm, follow-up lasted 8 weeks, and sample sizes were “determined by clinical and practical, rather than statistical, considerations”, with data presented descriptively. Aqueous humor was not sampled in this study, so pharmacokinetics and target engagement were assessed in serum only, where unbound ANX007 was not detected. The article states that there were no treatment-emergent adverse events after single injections, and in the same paragraph reports 8 ocular treatment-emergent adverse events and 1 systemic event, with all 9 participants (100.0%) having any treatment-emergent adverse event in its Table 2. The 5-mg dose was given in 100 μL, while the ongoing phase 3 ARCHER II trial administers 5 mg in a 25-microliter dose.